Peer-reviewedLicence not statedNew England Journal of Medicine24 Jun 2026

A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis

Francesca Conradie¹
Tasnim Badat¹
Asanda Poswa¹
Shakira Rajaram²
Shaneen Kooverjee²
Gary Maartens³
Graeme Meintjes^4,5
Jennifer Hughes⁶
Hendrik Simon Schaaf⁶
Pauline Howell²
Norbert O. Ndjeka⁷
Patrick P. J. Phillips⁸

8 affiliations

¹Isango Lethemba TB Research Unit, University of the Witwatersrand, Gqeberha, South Africa
²Clinical HIV Research Unit, University of the Witwatersrand, Johannesburg
³Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
⁴Department of Medicine, University of Cape Town, Cape Town, South Africa
⁵Queen Mary and Barts Health Tuberculosis Centre, Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London
⁶Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
⁷TB Control and Management, National Department of Health, Republic of South Africa, Pretoria
⁸UCSF Center for Tuberculosis, University of California, San Francisco, San Francisco

Open at source PDF DOI Cite

Treatment outcomes and post-treatment mortality among people with multidrug/rifampicin-resistant tuberculosis in Sierra Leone: a national cohort study
Faye Greenwood, Rashidatu Fouad Kamara, Ronnie Harding +4
The Lancet regional health. Africa1 Oct 2026Peer-reviewedCC BYFull textGeneral medicineEurope PMC
The Blind Spot of GeneXpert MTB/RIF: Isoniazid‐Resistant, Rifampicin‐Susceptible Tuberculosis Detected on Phenotypic Drug Susceptibility Testing
Hafiz Muhammad Faisal Nadeem, Ali Gohar, Muhammad Faisal Jakhar +3
Respirology case reports28 Oct 2026Peer-reviewedCC BY-NC-NDFull textInfectious diseaseEurope PMCEurope PMCPMC
Rapid detection of non-rifampicin resistant drug-resistant tuberculosis using Xpert MTB/XDR testing: Findings from a multisite drug-resistant tuberculosis case detection surge in Zambia
Phallon Blessing Mwaba, Marshal Sikandangwa, Robertson Chibumbya +10
PLOS Global Public Health23 Sep 2026Peer-reviewedCC BY 4.0Full textInfectious diseasePLOS
Prevalence of rifampicin-resistant tuberculosis and its associated factors among patients with tuberculosis at Galkayo General Hospital, Puntland, Somalia: a facility-based cross-sectional study.
Hawo Mohamud, Kirubel Minsamo Mishore, Bisrat Hagos +6
The Pan African medical journal8 Jun 2026Peer-reviewedCC BYFull textGeneral medicineEurope PMCPMC
Early sputum bacterial load dynamics predict treatment response in multidrug-resistant/rifampicin-resistant tuberculosis: A multicenter prospective cohort study
Fuzhen Zhang, Zilong Yang, Min Jiang +10
Journal of Infection23 Oct 2026Peer-reviewedCC BYFull textInfectious diseaseDOAJ

Cite

BibTeX RIS

BibTeX

@article{conradie2026pragmatic,
  title = {{A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis}},
  author = {Francesca Conradie and Tasnim Badat and Asanda Poswa and Shakira Rajaram and Shaneen Kooverjee and Gary Maartens and Graeme Meintjes and Jennifer Hughes and Hendrik Simon Schaaf and Pauline Howell and Norbert O. Ndjeka and Patrick P. J. Phillips},
  journal = {New England Journal of Medicine},
  year = {2026},
  month = jun,
  doi = {10.1056/nejmoa2503687},
  url = {https://doi.org/10.1101/2025.05.04.25326549},
}

RIS

TY  - JOUR
TI  - A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis
AU  - Francesca Conradie
AU  - Tasnim Badat
AU  - Asanda Poswa
AU  - Shakira Rajaram
AU  - Shaneen Kooverjee
AU  - Gary Maartens
AU  - Graeme Meintjes
AU  - Jennifer Hughes
AU  - Hendrik Simon Schaaf
AU  - Pauline Howell
AU  - Norbert O. Ndjeka
AU  - Patrick P. J. Phillips
PY  - 2026
DA  - 2026/06/24
JO  - New England Journal of Medicine
DO  - 10.1056/nejmoa2503687
UR  - https://doi.org/10.1101/2025.05.04.25326549
SN  - 0028-4793
SN  - 0096-6762
SN  - 1533-4406
SN  - 2331-4710
ER  -

Related

Cite